• Anvil Semiconductors

  Participated · Equity · Jan 2020

  Anvil Semiconductors commercializes silicon carbide (SiC)-on-silicon technology for power devices, aiming to deliver higher-efficiency power switches with lower carbon emissions and reduced running costs. The company has developed a proprietary process for epitaxial 3C‑SiC layers on silicon substrates that it says can cut manufacturing costs for SiC devices. Anvil’s long-term objective is to produce SiC materials and devices at costs close to conventional silicon to enable high-volume markets previously closed to SiC because of cost. The company was spun off in August 2010 from the University of Warwick’s School of Engineering by Warwick Ventures and is led by co-founder Dr Peter Ward and CEO Jill Shaw. Anvil is based in Coventry, UK, and the recent funding is intended to accelerate development and commercialization of its technology. No operating metrics such as revenue or user numbers are provided in the article. Anvil Semiconductors develops small power converters that use innovative Silicon Carbide (SiC) power semiconductor switches. The technology, developed by CEO Dr Peter Ward alongside Professor Phil Mawby’s team at the University of Warwick School of Engineering, aims to improve operating efficiency, reduce size and lower cost of power converters. Target applications cited include electric cars, photovoltaic cells and wind turbines. The company was created by Warwick Ventures Ltd, the university’s technology commercialization arm, and is newly launched. Its current financial support includes a £150k equity-style investment and an R&D grant from the Technology Strategy Board. The investment will support progress of the business and further technology development.

• Caption Data

  Participated · Equity · Jan 2014

  Caption Data supplies remote monitoring equipment and a real-time data monitoring service that lets customers access, assess and control equipment via PC, tablet or smartphone. The company’s solution monitors parameters such as temperature, humidity, vibration and power consumption. Its customer base includes construction companies, damage restoration firms and organisations such as the Environment Agency and water utilities in more than 14 countries. Caption Data is led by Managing Director Jon Penn and was formed in 2008. The company raised £100K in funding and intends to use the proceeds to expand operations. Operations are headquartered in Worcester, UK.

• Warwick Acoustics

  Participated · Equity · Nov 2013

  Warwick Acoustics develops in-car electrostatic speakers that deliver high sound quality while offering a slim profile for greater cabin-design flexibility. Its products are manufactured from upcycled, easy-to-recycle materials and do not use rare earth metals. The company is a spin-out from Warwick University’s engineering department and is led by CEO Dr Mike Grant. Warwick has already commercialized a range of premium headphone systems that have won over 30 industry awards and retail for up to £50,000. The company raised new funding to expand its manufacturing capabilities and scale production. It intends to invest in a state-of-the-art manufacturing facility and ramp up manufacturing capacity with the proceeds. Warwick Acoustics develops ElectroAcoustics Panel (EAP) systems that aim to improve in‑car acoustic performance while reducing weight and power consumption, and also builds premium personal and studio headphones. Its low‑profile EAP panels can be made in varied shapes to allow vehicle designers new styling options. Over the last 12 months the company demonstrated a full EAP system in a vehicle, completed three customer‑funded proof‑of‑concept projects and passed key automotive environmental tests. The firm launched the BRAVURA premium electrostatic headphone in September, with orders already exceeding the initial production run, and supplies the audio industry across four continents. Established in 2002 as a University of Warwick spin‑out, Warwick Acoustics employs 30 people at its headquarters at Mira Technology Park in Nuneaton. The company plans to use recent funding to accelerate development and commercialization of its first in‑car systems and capitalise on recent commercial progress.

• Lightpoint Medical

  Participated · Seed · Jun 2013

  Lightpoint Medical develops intraoperative imaging products, notably a robotic laparoscopic probe designed to detect cancer in real time and the LightPath® Imaging System. The LightPath system has already achieved commercial sales throughout Europe. The laparoscopic probe is intended to bring real-time cancer detection to minimally invasive and robotic surgery to improve tissue-sparing and clinical outcomes. The company will use new funding to commercialise the laparoscopic probe and support commercial growth of the LightPath system. It has secured a £5 million financing and previously raised more than £3 million in grant funding from the Horizon 2020 SME Instrument and Innovate UK. Management says the funds will prepare the company for commercial scale-up and a commercial launch of the laparoscopic probe. Lightpoint Medical, based in Rickmansworth, United Kingdom and Cambridge, Massachusetts, develops the EnLight™ fiberscope system that uses molecular imaging to reveal microscopic cancer deposits. The technology is intended to enable surgeons to identify cancerous tissue during procedures. The company will use the awarded funds to support clinical trials of EnLight™ in lymph node cancer and a range of gynecologic cancers at Memorial Sloan Kettering Cancer Center (MSK). Lightpoint will collaborate on the research with MSK’s Drs. Jan Grimm and Nadeem Abu-Rustum. The company is led by Founder and CEO Dr. David Tuch and is backed by business angels and other private investors. Lightpoint Medical develops surgical imaging technologies, including its lead products LightPath™ and EnLight™, to help surgeons detect cancer in real time and reduce the need for repeat operations. The company has clinical trials underway in breast, prostate and stomach cancer. Led by CEO Dr David Tuch, Lightpoint is UK-based and completed a Series A raise of £2m ($3.1m). The company intends to use the funds to bring LightPath and EnLight to the US and European markets in 2015. Its technology is positioned for intraoperative cancer detection to improve surgical outcomes and reduce follow-up procedures. Lightpoint Medical is a Rickmansworth, UK–based developer of innovative imaging technologies for cancer surgery. Founded in 2012 by Dr David Tuch, the company is developing a novel molecular imaging technology based on Cerenkov luminescence imaging. The technology is intended to help surgeons detect cancer in real time during surgery, providing more accurate treatment while sparing healthy tissue. In June 2013 the company raised £175K (approximately $270K) in seed funding. The round involved a mix of institutional and angel investors led by Oxford Technology Management.

• Aeristech Limited

  Participated · Equity · Jun 2010

  Aeristech Limited entered a subscription agreement on February 25, 2021 for a pre-IPO private placement of 2,125,000 shares at £2.40 per share. The placement is expected to raise gross proceeds of £5,100,000 at a fully diluted post-money valuation of £37,800,000. Investors in the transaction included Vela Technologies PLC, Sabien Technology Group Plc and SAIC Venture Capital. Vela subscribed for 145,833 shares for proceeds of £350,000 (acquiring a 0.92% stake) and Sabien subscribed for 41,667 shares for proceeds of £100,000 (acquiring a 0.3% stake). The company also issued 36,458 warrants to Vela and 10,417 warrants to Sabien, exercisable at £2.40 per share for a two-year period. The transaction was structured as a pre-IPO private placement of equity with attached warrants. Aeristech develops a patented Hybrid Turbocharger Technology (HTT) system intended to enable smaller engines to deliver the performance of larger ones. The HTT system is claimed to generate 20–30% fuel savings and to reduce exhaust emissions by 20–30%. The company has used incubation support from The Carbon Trust during initial development. Aeristech has secured external funding to advance its programmes and testing. The recent financing will be used to progress testing programmes for the HTT system with two global vehicle manufacturers. The company is based in Birmingham, UK.

No current team members are available.